Arcellx (ACLX) Income towards Parent Company (2021 - 2025)
Arcellx's quarterly Income towards Parent Company came in at -$58.1 million in Q4 2025, down 23.43% year-on-year from -$75.9 million in Q4 2024, and down 4.18% quarter-over-quarter from -$55.8 million in Q3 2025.
Arcellx has reported Income towards Parent Company for 5 years, with the latest figure at -$58.1 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 23.43% year-over-year to -$58.1 million; the trailing twelve-month figure through Dec 2025 stood at -$228.9 million (down 113.39% YoY), and the FY2025 full-year result was -$228.9 million, down 113.26% from the prior year.
- Income towards Parent Company for Q4 2025 stood at -$58.1 million, down from -$55.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was $19.8 million in Q4 2023, with the low at -$92.9 million in Q3 2022.
- Average Income towards Parent Company over 5 years is -$33.0 million, with a median of -$27.3 million recorded in 2023.
- Year-over-year, Income towards Parent Company surged 150.89% in 2023 and tumbled 765.1% in 2025.
- Tracing ACLX's Income towards Parent Company over 5 years: stood at -$20.7 million in 2021, then tumbled by 88.39% to -$39.0 million in 2022, then surged by 150.89% to $19.8 million in 2023, then slumped by 337.26% to -$47.1 million in 2024, then retreated by 23.43% to -$58.1 million in 2025.
- The last three Income towards Parent Company figures came in at -$58.1 million (Q4 2025), -$55.8 million (Q3 2025), and -$52.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -58.11 Mn |
| Sep 30, 2025 | -55.78 Mn |
| Jun 30, 2025 | -52.77 Mn |
| Mar 31, 2025 | -62.27 Mn |
| Dec 31, 2024 | -47.08 Mn |
| Sep 30, 2024 | -25.84 Mn |
| Jun 30, 2024 | -27.16 Mn |
| Mar 31, 2024 | -7.20 Mn |
| Dec 31, 2023 | 19.84 Mn |
| Sep 30, 2023 | -39.34 Mn |
| Jun 30, 2023 | -23.85 Mn |
| Mar 31, 2023 | -27.34 Mn |
| Dec 31, 2022 | -38.99 Mn |
| Sep 30, 2022 | -92.87 Mn |
| Jun 30, 2022 | -30.77 Mn |
| Mar 31, 2022 | -26.04 Mn |
| Dec 31, 2021 | -20.70 Mn |
| Sep 30, 2021 | -17.11 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -11.28 Mn |